Octave Specialty Group (OSG) Earnings Dates, Call Summary & Reports

Compare

167 Followers

Earnings Data

Report Date

May 11, 2026

After Close (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

0.07

Last Year’s EPS

-0.13

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 2 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 23, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presented a constructive growth story driven by a rapidly scaling Insurance Distribution platform, strong organic and Ventures revenue growth, margin improvement in distribution, accretive high-margin acquisition (ArmadaCare), AI/tech differentiation, and clear 2026 guidance. These positives were offset by transitional reported losses driven by acquisition and one-time corporate costs, impairments, start-up investment drag, and near-term pressure in some P&C pricing areas. Management framed the negatives as largely transactional and part of a multi-year scaling strategy, with several metrics (adjusted EBITDA, distribution margins, Ventures growth, combined ratio) trending favorably toward management targets.

Company Guidance

Octave guided to tangible 2026 targets: Insurance Distribution is expected to deliver at least 20% organic revenue growth and roughly $40 million of adjusted EBITDA (with segment margins trending toward mid-20s over time; Q4 '25 adj. EBITDA margin was 15% and operating basis 22.6%), Specialty Insurance (including Everspan) is projected to write about $410 million of gross written premiums and produce approximately $7.5 million of adjusted EBITDA, corporate adjusted expenses are expected to be below $30 million, and consolidated adjusted net income is targeted at about $0.50 per share; management also said NCI buy-ins this year should be less than $50 million (to be funded from cash and modest incremental borrowing), net investment income should be flat to marginally higher, equity-based comp should be down a few million versus 2025, ArmadaCare contributes >40% EBITDA margins and A&H earnings are seasonally weighted (about 60% in Q1), and corporate expense-reduction initiatives are estimated to yield roughly $17 million of reported savings (and >$10 million benefit to adjusted corporate EBITDA) when fully realized.

Strong Insurance Distribution Revenue Growth

Insurance Distribution business revenue grew 65% over 2024, including 14% organic growth (note: excludes 8 months of Octave Ventures and ArmadaCare acquisition).

Octave Ventures Rapid Expansion

Octave Ventures standalone organic revenue growth increased from ~18% in 2024 to ~47% in 2025, reflecting strong incubator performance and pipeline.

Quarterly Production and Commission Growth

In Q4 2025, Insurance Distribution premium production grew 9%, commission revenue grew 13%, and organic revenue increased just over 8% year-over-year.

Adjusted EBITDA Improvement (Distribution and Consolidated Adjusted)

Adjusted EBITDA from continuing operations rose to $1.4M in Q4 2025 vs $0.5M in Q4 2024. Insurance Distribution adjusted EBITDA to shareholders increased to just over $7M from just over $5M, a 33% increase.

Improving Distribution Margins

Insurance Distribution adjusted EBITDA margin improved to 15% in Q4 2025 from 12% a year earlier and operating basis adjusted EBITDA was over $10M at a 22.6% margin (vs just under $10M and 22.3% prior year), trending toward mid-20s target.

ArmadaCare Acquisition Adds High-Margin A&H Scale

ArmadaCare acquired in Q4 2025 enhances A&H exposure and adds recurring revenue with attractive EBITDA margins of over 40%; integration progressed ahead of schedule and early performance exceeded expectations (2 months contribution in Q4).

Everspan Repositioning Showing Improvement

After repositioning, Everspan reported an effective loss & LAE ratio (including sliding scale commissions) of 62.9% in Q4 2025 vs 66.8% in Q4 2024 (down nearly 4 percentage points). Combined ratio fell below 100% to 99.4% for the first time this year with expectation to remain <100% in 2026.

Everspan Premium Growth

Everspan gross premiums written rose 34% to $80M in Q4 2025; net premiums written improved from negative $3M in prior year to $23M; net earned premium was roughly flat year-over-year.

Corporate Cost Reduction Momentum

Adjusted corporate G&A decreased to $7.5M in Q4 2025 from $8.8M in Q4 2024. Selected corporate expense reduction initiatives are expected to generate ~ $17M of reported expense savings and > $10M impact on adjusted corporate EBITDA when fully complete.

Clear 2026 Guidance and Growth Targets

2026 guidance: Insurance Distribution organic revenue growth of at least 20% and adjusted EBITDA ~ $40M; Specialty Insurance GWP ~ $410M and adjusted EBITDA ~ $7.5M; corporate adjusted expenses below $30M; consolidated adjusted net income ~ $0.50 per share.

Technology and AI-Driven Differentiation

Launched proprietary AI platform 'Hammurabi' for medical stop-loss, contributing to record ESL results; management is integrating AI/data tools across MGAs to improve risk selection, pricing and operational efficiency.

Embedded Growth Pipeline of New MGAs

9 of 22 MGAs were launched in 2024-2025; over 40% of MGAs are in early growth stages with many expected to contribute materially to future organic revenue and earnings; management expects most startup losses to improve with all but 2 of 6 negative-EBITDA entities anticipated to be breakeven/profitable by Q4 2026.

Octave Specialty Group (OSG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

OSG Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 11, 2026	2026 (Q1)	0.07 / -	-0.13	―	―	―
Feb 23, 2026	2025 (Q4)	-0.15 / -0.02	-0.12	83.33% (+0.10)
Nov 10, 2025	2025 (Q3)	-0.20 / -0.21	-0.46	54.35% (+0.25)
Aug 07, 2025	2025 (Q2)	-0.19 / -0.22	0.18	-222.22% (-0.40)
May 12, 2025	2025 (Q1)	-0.07 / -0.13	0.82	-115.85% (-0.95)
Feb 26, 2025	2024 (Q4)	0.00 / -0.12	0.32	-137.50% (-0.44)
Nov 12, 2024	2024 (Q3)	0.08 / -0.46	2	-123.00% (-2.46)
Aug 05, 2024	2024 (Q2)	0.15 / 0.18	0.07	157.14% (+0.11)
May 06, 2024	2024 (Q1)	0.09 / 0.82	-0.3	373.33% (+1.12)
Feb 27, 2024	2023 (Q4)	-0.02 / 0.32	4.18	-92.34% (-3.86)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

OSG Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 23, 2026	$5.64	$5.09	-9.75%
Nov 10, 2025	$8.69	$10.08	+16.00%
Aug 07, 2025	$8.29	$6.94	-16.28%
May 12, 2025	$8.35	$6.70	-19.76%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Octave Specialty Group (OSG) report earnings?

Octave Specialty Group (OSG) is schdueled to report earning on May 11, 2026, After Close (Confirmed).

What is Octave Specialty Group (OSG) earnings time?

Octave Specialty Group (OSG) earnings time is at May 11, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is OSG EPS forecast?

OSG EPS forecast for the fiscal quarter 2026 (Q1) is 0.07.